Research
Hormonal
Liraglutide, dulaglutide, semaglutide, and tirzepatide individually reduced the incidence of PRSA compared to the reference arm.
Each GLP-1/dual agonist may be effective in reducing sleep apnea incidence, offering multiple treatment options.
StrongSupportsmedium confidence
Individually, all drugs were able to reach this outcome as compared to the reference arm: liraglutide (HR, 0.64 [95% CI, 0.51-0.80]), dulaglutide (HR, 0.32 [95% CI, 0.28-0.36]), semaglutide (HR, 0.57 [95% CI, 0.54-0.61]), and tirzepatide (HR, 0.74 [95% CI, 0.67-0.92]).
Why this rating
Based on a large retrospective cohort study design.
Source
Impact of GLP-1 and dual agonists on the incidence of new cases of physician-reported sleep apnea: a real-world study
Beatriz S Prado et al. · Annals of the American Thoracic Society · 2026
cohort · n=1253188Cited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →